Spevigo
Named-patient access overview. Spevigo is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Spevigo (spesolimab-sbzo) is a humanised anti-interleukin-36 receptor (anti-IL-36R) IgG1 monoclonal antibody developed by Boehringer Ingelheim. The US Food and Drug Administration first approved Spevigo in September 2022 for the treatment of generalised pustular psoriasis (GPP) flares in adults and adolescents, with a label expansion in March 2024 to cover ongoing treatment of GPP in patients 12 years and older. For an active flare Spevigo is administered as a single 900 mg intravenous infusion over 90 minutes, with an optional second 900 mg dose one week later if symptoms persist. For ongoing GPP treatment between flares it is given subcutaneously as a 600 mg loading dose followed by 300 mg every four weeks. Administration is typically coordinated through a specialist dermatology or hospital infusion setting with appropriate monitoring for infusion reactions and infection risk.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Spevigo
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Spevigo is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country access guide for Spevigo in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Spevigo
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.